Keyword results: Roche


Open Orphan – can these Covid 19 antibody testing numbers be correct? Clarifying RNS needed ASAP

Last night Cathal Friel gave a a video interview on behalf of Open Orphan (ORPH)where he discussed a new test for Covid antibodies, like the Roche one, that open Orphan is involved in rolloing out. The video is below. An RNS to clarify quite extraordinary numbers given by Cathal in this interview is, IMHO, needed asap.

Subscribe to ShareProphets to access Premium Content

It's Hard to See How the Big Pharmas Won't Prosper Once the Virus Retreats

Hello, Share Trawlers. Here’s another suggestion for your plans to buy more shares once the virus is on its way out. Today’s choice is big pharma companies, like GlaxoSmithKline (GSK) and AstraZeneca (AZN). There are also a few foreign listed companies, like Roche and Johnson & Johnson, that you might consider...


Novacyt is being pumped on coronavirus fears but my money would be on pharma giants like Roche to provide most of the tests - as Public Enemy rapped, 'Don't believe the hype'

I wondered how long it would take before people started trying to cash in off of the back of coronavirus and pushing shares in small AIM listed companies that are supposedly going to make a fortune from this outbreak.

Subscribe to ShareProphets to access Premium Content

Good News Keeps On Flowing for this Yorkshire Medical Pioneer

Hello Share Swashers. This may be the first time I’ve written three wall-to-wall articles about any company. But yet more positive news has broken from Avacta (AVCT), the medical pioneer. And I think it makes considering this interesting share even more compelling...


Immunocore announces good news - Neil Woodford can breathe a sigh of relief, for now

Privately held Immunocore, which forms part of the Neil Woodford estate, has announced some good news: it has signed a deal with Genetech, part of Roche Group, for the development of Immunocore’s IMC-C103C drug aimed at targeting the MAGE-A4 protein (Melanoma-Associated Antigen A4). The really good news is that Genetech is to hand over $100 million in upfront and near-term milestone payments, and upon establishing proof-of-concept there is an option to co-develop the treatment or license the treatment to Genetech for royalty and milestone payments. Needless to say, Woodford Patient Capital Trust (WPCT) rushed out a statement too...

Subscribe to ShareProphets to access Premium Content

There's Hope in the Shire - and We're Not About Middle Earth.

Hello Share Bottlers.  I stand by my belief for the six months or so that small and medium pharmaceutical concerns, and possibly the giants, too, are going to see higher profits over the next few years. It’s a question of growing demand from an ageing or obese population - and, in fact, both.

Roche buys Ariosa – Panmure’s bullish Read across for Premaitha

Today Pharma giant Roche has snapped up a California based form Ariosa which is big in what is termed NIPT. Panmure Gordon, house broker to Premaitha (NIPT) reckons this has a clear read across for its AIM listed client. In a note sent out today it writes:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments